HIV prevention shot studied in real-world women

NCT ID NCT06145854

Ongoing Prevention Sponsor: Midway Specialty Care Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 100 cisgender women in the southern U.S. who are already prescribed long-acting cabotegravir injections (Apretude) for HIV prevention. Over two years, researchers will track how many women stick with the shots, how satisfied they are, and rates of other sexually transmitted infections. The goal is to see how this newer option works outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabotegravir injection (Apretude)
What this could lead to: If successful, this study could show that long-acting injections are a practical and effective HIV prevention option for cisgender women in real-world settings.
What could go wrong: This is an observational study with no control group, so it cannot prove cause and effect. Results may not apply to other populations or regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Midway Specialty Care Center

Orlando, Florida, 32819, United States
Midway Specialty Care Center

Temple Terrace, Florida, 33617, United States
Midway Specialty Care Center

West Palm Beach, Florida, 33401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.